Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study.
Biomarkers
Disease progression
GFAP
Parkinson’s disease
Prospective cohort study
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
06 11 2023
06 11 2023
Historique:
received:
20
06
2023
accepted:
19
10
2023
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
Reactive astrogliosis has been demonstrated to have a role in Parkinson's disease (PD); however, astrocyte-specific plasma glial fibrillary acidic protein (GFAP)'s correlation with PD progression remains unknown. We aimed to determine whether plasma GFAP can monitor and predict PD progression. A total of 184 patients with PD and 95 healthy controls (HCs) were included in this prospective cohort study and followed-up for 5 years. Plasma GFAP, amyloid-beta (Aβ), p-tau181, and neurofilament light chain (NfL) were measured at baseline and at 1- and 2-year follow-ups. Motor and non-motor symptoms, activities of daily living, global cognitive function, executive function, and disease stage were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) part III, UPDRS-I, UPDRS-II, Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), and Hoehn and Yahr (H&Y) scales at each visit, respectively. Plasma GFAP levels were higher in patients with PD (mean [SD]: 69.80 [36.18], pg/mL) compared to HCs (mean [SD]: 57.89 [23.54], pg/mL). Higher levels of GFAP were observed in female and older PD patients. The adjusted linear mixed-effects models showed that plasma GFAP levels were significantly associated with UPDRS-I scores (β: 0.006, 95% CI [0.001-0.011], p = 0.027). Higher baseline plasma GFAP correlated with faster increase in UPDRS-I (β: 0.237, 95% CI [0.055-0.419], p = 0.011) and UPDRS-III (β: 0.676, 95% CI [0.023-1.330], p = 0.043) scores and H&Y stage (β: 0.098, 95% CI [0.047-0.149], p < 0.001) and faster decrease in MoCA (β: - 0.501, 95% CI [- 0.768 to - 0.234], p < 0.001) and FAB scores (β: - 0.358, 95% CI [- 0.587 to - 0.129], p = 0.002). Higher baseline plasma GFAP predicted a more rapid progression to postural instability (hazard ratio: 1.009, 95% CI [1.001-1.017], p = 0.033). Plasma GFAP might be a potential biomarker for monitoring and predicting disease progression in PD.
Sections du résumé
BACKGROUND
Reactive astrogliosis has been demonstrated to have a role in Parkinson's disease (PD); however, astrocyte-specific plasma glial fibrillary acidic protein (GFAP)'s correlation with PD progression remains unknown. We aimed to determine whether plasma GFAP can monitor and predict PD progression.
METHODS
A total of 184 patients with PD and 95 healthy controls (HCs) were included in this prospective cohort study and followed-up for 5 years. Plasma GFAP, amyloid-beta (Aβ), p-tau181, and neurofilament light chain (NfL) were measured at baseline and at 1- and 2-year follow-ups. Motor and non-motor symptoms, activities of daily living, global cognitive function, executive function, and disease stage were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) part III, UPDRS-I, UPDRS-II, Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), and Hoehn and Yahr (H&Y) scales at each visit, respectively.
RESULTS
Plasma GFAP levels were higher in patients with PD (mean [SD]: 69.80 [36.18], pg/mL) compared to HCs (mean [SD]: 57.89 [23.54], pg/mL). Higher levels of GFAP were observed in female and older PD patients. The adjusted linear mixed-effects models showed that plasma GFAP levels were significantly associated with UPDRS-I scores (β: 0.006, 95% CI [0.001-0.011], p = 0.027). Higher baseline plasma GFAP correlated with faster increase in UPDRS-I (β: 0.237, 95% CI [0.055-0.419], p = 0.011) and UPDRS-III (β: 0.676, 95% CI [0.023-1.330], p = 0.043) scores and H&Y stage (β: 0.098, 95% CI [0.047-0.149], p < 0.001) and faster decrease in MoCA (β: - 0.501, 95% CI [- 0.768 to - 0.234], p < 0.001) and FAB scores (β: - 0.358, 95% CI [- 0.587 to - 0.129], p = 0.002). Higher baseline plasma GFAP predicted a more rapid progression to postural instability (hazard ratio: 1.009, 95% CI [1.001-1.017], p = 0.033).
CONCLUSIONS
Plasma GFAP might be a potential biomarker for monitoring and predicting disease progression in PD.
Identifiants
pubmed: 37932720
doi: 10.1186/s12916-023-03120-1
pii: 10.1186/s12916-023-03120-1
pmc: PMC10626747
doi:
Substances chimiques
Biomarkers
0
Glial Fibrillary Acidic Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
420Informations de copyright
© 2023. The Author(s).
Références
J Neurochem. 2014 Sep;130(6):805-15
pubmed: 24749759
Alzheimers Dement. 2023 Jan;19(1):25-35
pubmed: 35234335
JAMA Neurol. 2021 Dec 1;78(12):1471-1483
pubmed: 34661615
J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):263-270
pubmed: 31937580
Exp Neurobiol. 2021 Jun 30;30(3):222-231
pubmed: 34045369
Ann Neurol. 2020 Dec;88(6):1065-1076
pubmed: 32799383
Front Neurol. 2021 Feb 05;12:631145
pubmed: 33613437
Alzheimers Res Ther. 2020 Sep 28;12(1):118
pubmed: 32988409
Mov Disord. 2022 Feb;37(2):421-426
pubmed: 34719813
Alzheimers Dement. 2022 Jun;18(6):1141-1154
pubmed: 34494715
PLoS One. 2021 Oct 7;16(10):e0257372
pubmed: 34618817
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Alzheimers Res Ther. 2021 Mar 27;13(1):68
pubmed: 33773595
J Parkinsons Dis. 2022;12(5):1527-1538
pubmed: 35466956
Lancet Neurol. 2019 Oct;18(10):953-961
pubmed: 31451409
J Neural Transm (Vienna). 2022 Jun;129(5-6):545-555
pubmed: 35364741
Front Aging Neurosci. 2020 Jul 22;12:156
pubmed: 32792937
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Neurology. 2019 Sep 10;93(11):e1104-e1111
pubmed: 31420461
NPJ Parkinsons Dis. 2021 Jul 15;7(1):58
pubmed: 34267217
J Biol Chem. 2010 Mar 19;285(12):9262-72
pubmed: 20071342
Neurobiol Dis. 2023 Sep;185:106237
pubmed: 37499883
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
Brain. 2021 Dec 16;144(11):3505-3516
pubmed: 34259835
Transl Psychiatry. 2021 Jan 11;11(1):27
pubmed: 33431793
J Alzheimers Dis. 2020;77(3):1129-1141
pubmed: 32804092
Front Neurosci. 2022 Jun 24;16:882316
pubmed: 35812232
Neurosci Lett. 2017 Sep 14;657:166-170
pubmed: 28802830
BMC Psychiatry. 2012 Sep 25;12:156
pubmed: 23009126
Mol Brain. 2010 Apr 21;3:12
pubmed: 20409326
Ann Neurol. 2023 Jan;93(1):184-195
pubmed: 36331161
NPJ Parkinsons Dis. 2022 Nov 12;8(1):154
pubmed: 36371469
J Inflamm Res. 2021 Dec 30;14:7501-7506
pubmed: 35002283
Neurology. 2010 Sep 21;75(12):1055-61
pubmed: 20720189
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Brain Commun. 2022 Aug 18;4(5):fcac199
pubmed: 36072646
Ann Clin Transl Neurol. 2023 May;10(5):802-813
pubmed: 37000892
Brain Behav Immun. 2023 Oct;113:124-135
pubmed: 37394144
Brain. 2019 Oct 1;142(10):3116-3128
pubmed: 31504212
Front Pharmacol. 2021 Nov 26;12:746491
pubmed: 34899299
Front Cell Neurosci. 2014 Aug 04;8:211
pubmed: 25136294
Nat Rev Neurol. 2022 Mar;18(3):158-172
pubmed: 35115728
J Alzheimers Dis. 2019;67(2):481-488
pubmed: 30594925
Clin Neurol Neurosurg. 2012 May;114(4):372-5
pubmed: 22206859
Alzheimers Dement. 2020 Apr;16(4):681-695
pubmed: 31879236
Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18(2):68-74
pubmed: 15249850
Redox Biol. 2017 Aug;12:162-170
pubmed: 28237879
J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1234-1243
pubmed: 31444276
J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1112-8
pubmed: 21593513